Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Harrow Health, Inc.NASDAQ: HROW
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 15.2% from a year ago
Total assets stood at $419.54M at the end of Q1 FY2026, up 15.2% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +36.4% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +15.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 399.48M USD
- Year-over-year change
- +2.7%
- 4-year CAGR
- +42.0%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 399.48M | +2.7% |
| FY2024 | 2024-12-31 | 388.97M | +24.8% |
| FY2023 | 2023-12-31 | 311.76M | +98.1% |
| FY2022 | 2022-12-31 | 157.38M | +60.1% |
| FY2021 | 2021-12-31 | 98.33M | — |
Total Assets vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +15.2% is the 3rd highest of 8, against a peer median of +0.2%.
- Over three fiscal years its annual growth of +36.4% compares with a peer median of +26.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $13.86B USD | +0.2% | +8.0% | |
| Mar 2026 | $732.53M USD | +80.5% | +75.6% | |
| Sep 2026 | $505.5M USD | -5.4% | +35.1% | |
| Mar 2026 | $419.54M USD | +15.2% | +36.4% | |
| Mar 2026 | $288.22M USD | -20.5% | +26.4% | |
| Mar 2026 | CHF 243.26M CHF | +19.1% | +85.4% | |
| Sep 2026 | $209.41M USD | -4.0% | -19.2% | |
| Mar 2026 | $21.89M USD | +14.8% | -13.3% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $18.64M USD | — | — |
| Peer median (excluding HROW) | — | +0.2% | +26.4% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.17M | 96.27M | 74.09M | 47.25M | 72.93M |
| Short-term Investments | 8.5M | 5.59M | 8.68M | 0 | 0 |
| Net Receivables | 4.52M | 6.39M | 36.49M | 116.6M | 110.9M |
| Inventory | 4.22M | 6.54M | 10.87M | 10.7M | 13.52M |
| Other Current Assets | 92K | 118K | 1.75M | 3.41M | 2.13M |
| Total Current Assets | 60.66M | 118.26M | 139.07M | 189.65M | 211.75M |
| Property, Plant & Equipment (Net) | 9.08M | 11M | 12.44M | 12.29M | 11.04M |
| Goodwill | 332K | 332K | 332K | 332K | 332K |
| Intangible Assets | 17.13M | 25.84M | 159.91M | 186.7M | 175.17M |
| Long-term Investments | 11.13M | 0 | 0 | 0 | 0 |
| Tax Assets | (12.45M) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.45M | 1.95M | 0 | 0 | 1.18M |
| Total Non-current Assets | 37.67M | 39.12M | 172.68M | 199.32M | 187.73M |
| Total Assets | 98.33M | 157.38M | 311.76M | 388.97M | 399.48M |
| Account Payables | 5.17M | 6.44M | 21.42M | 38.76M | 35.36M |
| Short-term Debt | 0 | 0 | 806K | 0 | 887K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 16K | 113K | 0 | 44K | 788K |
| Other Current Liabilities | 1.16M | 0 | 21.66M | 0 | 59.27M |
| Total Current Liabilities | 9.72M | 18.63M | 49.34M | 91.34M | 96.3M |
| Long-term Debt | 71.65M | 104.17M | 183.17M | 219.54M | 243.18M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 2.71M | 0 | 0 |
| Total Non-current Liabilities | 77.68M | 111.51M | 192.41M | 228.33M | 251.09M |
| Total Liabilities | 87.4M | 130.14M | 241.75M | 319.67M | 347.39M |
| Common Stock | 27K | 30K | 35K | 35K | 37K |
| Retained Earnings | (95.41M) | (109.49M) | (133.9M) | (151.39M) | (156.52M) |
| Accumulated OCI | 0 | 0 | (409K) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (355K) | (355K) | (355K) | (355K) | (355K) |
| Total Equity | 10.93M | 27.24M | 70M | 69.3M | 52.09M |
| Total Debt | 77.96M | 112.23M | 190.5M | 228.83M | 251.98M |
| Net Debt | 35.79M | 15.96M | 116.42M | 181.58M | 179.05M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.